Epperla, N., Maddocks, K. J., Salhab, M., Chavez, J. C., Reddy, N., Karmali, R., … Costa, L. J. (2017). C‐MYC–positive relapsed and refractory, diffuse large B‐cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy. Cancer, 123(22), 4411–4418. https://doi.org/10.1002/cncr.30895

Epperla, Narendranath, Kami J. Maddocks, Mohammed Salhab, Julio C. Chavez, Nishitha Reddy, Reem Karmali, Elvira Umyarova, et al. “C‐MYC–positive relapsed and refractory, diffuse large B‐cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy.” Cancer 123, no. 22 (November 15, 2017): 4411–18. https://doi.org/10.1002/cncr.30895.

Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, et al. C‐MYC–positive relapsed and refractory, diffuse large B‐cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy. Cancer. 2017 Nov 15;123(22):4411–8.

Epperla, Narendranath, et al. “C‐MYC–positive relapsed and refractory, diffuse large B‐cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy.” Cancer, vol. 123, no. 22, Wiley, Nov. 2017, pp. 4411–18. Crossref, doi:10.1002/cncr.30895.

Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez‐Ilizaliturri FJ, Al‐Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evans A, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ. C‐MYC–positive relapsed and refractory, diffuse large B‐cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy. Cancer. Wiley; 2017 Nov 15;123(22):4411–4418.